Full disclosure before we get into this one: I’m a shots-for-life girlie. I don’t have plans to switch off my injectable anytime soon.
But I also know I’m not the only voice in this community, and one of the most common fears I hear from people thinking about life after an injectable GLP-1 is simple: what happens to the weight once I stop?
A new trial just gave us a useful answer, and a new tool, for people wrestling with that exact question.
The Trial
The trial, called ATTAIN-MAINTAIN, was led by Dr. Louis Aronne at Weill Cornell Medicine and published in Nature Medicine. It followed 376 people who’d already been on an injectable GLP-1, either tirzepatide or semaglutide, as part of an earlier trial called SURMOUNT-5, and had reached a weight plateau, defined as less than a 5% change over a 12-week window.
Instead of just stopping treatment cold, researchers randomized these plateaued patients to either a once-daily oral GLP-1 called orforglipron or a placebo, then tracked their weight over the following year.
A Bridge, Not a Cliff
The results make a real case for the oral option as a bridge, rather than a cliff, off injectable treatment.
In the group that had been on tirzepatide, people who switched to orforglipron held onto 74.7% of their previous weight loss, compared to just 49.2% for the placebo group. The gap was even larger in the semaglutide group, with 79.3% maintaining on orforglipron versus 37.6% on placebo.
In real numbers, that meant an average weight gain of about 11 pounds for tirzepatide patients on orforglipron, versus considerably more on placebo, and just 2.2 pounds for semaglutide patients who switched to orforglipron.
Why the Two Groups Split
That gap between the tirzepatide and semaglutide groups isn’t a fluke, and Dr. Aronne explains exactly why in the study.
Tirzepatide works on two hormone receptors, GIP and GLP-1, while both semaglutide and orforglipron work on only one… GLP-1. Going from a dual-receptor medication to a single-receptor one is expected to come with some regain, simply because you’re stepping down in mechanism, not because orforglipron isn’t doing its job.
Semaglutide-to-orforglipron patients, by contrast, stayed within the same single-receptor mechanism, which likely explains why that group held on to even more of their results.
More Than the Scale
It wasn’t just the number on the scale, either. Across both groups, people maintained their reductions in waist circumference and held onto or even improved their blood sugar markers, insulin levels, cholesterol, and blood pressure.
Side effects stayed in familiar GLP-1 territory, mostly mild to moderate nausea, constipation, and GI symptoms, with serious adverse events showing up in under 2% of patients.
Why This Actually Matters
These results matter because cost, storage, and needle fatigue are real barriers that keep people from staying on injectable therapy long-term, even when the medication itself is working.
An oral option that preserves most of the benefit gives people a true off-ramp, rather than the binary choice a lot of patients have felt stuck with until now, stay on an injectable indefinitely or risk losing your progress entirely.
Two Important Caveats
There is some important context for this study you need to know.
First, this study measured maintenance over one year, so we don’t yet know what these numbers look like at three or five years out.
Second, Dr. Aronne, the trial’s lead investigator, is a paid consultant for Eli Lilly, the study’s sponsor and the manufacturer of both orforglipron and tirzepatide, and a paid advisor for Novo Nordisk, which makes semaglutide.
To be clear, that doesn’t invalidate the findings. This was a randomized, placebo-controlled trial, which is a rigorous design. However, it’s the kind of financial relationship you should know about when you’re reading results this favorable to a company’s own product.
Good News From any Angle
Whatever your own approach to this medication looks like, shots for life or eyeing an eventual off-ramp, this finding is good news for the field. It’s one more piece of evidence that managing obesity long-term doesn’t have to mean one rigid path.
There’s a tool that appears to work as a bridge for those who need one, and confirmation, again, that the drop-everything-and-regain-it-all fear many people carry isn’t the inevitable outcome it’s made out to be.
